BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30632208)

  • 1. Dornase alfa during lower respiratory tract infection post-lung transplantation: a randomized controlled trial.
    Tarrant BJ; Snell G; Ivulich S; Button B; Thompson B; Holland A
    Transpl Int; 2019 Jun; 32(6):603-613. PubMed ID: 30632208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
    Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled mannitol for cystic fibrosis.
    Nolan SJ; Thornton J; Murray CS; Dwyer T
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008649. PubMed ID: 26451533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
    Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
    J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.
    Tarrant BJ; Le Maitre C; Romero L; Steward R; Button BM; Thompson BR; Holland AE
    Respirology; 2017 Aug; 22(6):1084-1092. PubMed ID: 28397992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
    Cimmino M; Nardone M; Cavaliere M; Plantulli A; Sepe A; Esposito V; Mazzarella G; Raia V
    Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.
    Geller DE; Eigen H; Fiel SB; Clark A; Lamarre AP; Johnson CA; Konstan MW
    Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.
    Johnson CA; Butler SM; Konstan MW; Breen TJ; Morgan WJ
    J Pediatr; 1999 Jun; 134(6):734-9. PubMed ID: 10356143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
    Fitzgerald DA; Hilton J; Jepson B; Smith L
    Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change.
    VanDevanter DR; Craib ML; Pasta DJ; Millar SJ; Morgan WJ; Konstan MW;
    Pediatr Pulmonol; 2018 Jan; 53(1):43-49. PubMed ID: 29064184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerosolized dornase alfa in cystic fibrosis: is there a role in the management of patients with early obstructive lung disease?
    Geller DE
    Pediatr Pulmonol; 1997 Aug; 24(2):155-8; discussion 159-61. PubMed ID: 9292913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial.
    Wilson CJ; Robbins LJ; Murphy JM; Chang AB
    Pediatr Pulmonol; 2007 Dec; 42(12):1110-6. PubMed ID: 17955550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucoactive agents for adults with acute lung conditions: A systematic review.
    Tarrant BJ; Maitre CL; Romero L; Steward R; Button BM; Thompson BR; Holland AE
    Heart Lung; 2019; 48(2):141-147. PubMed ID: 30409442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.
    Sawicki GS; Chou W; Raimundo K; Trzaskoma B; Konstan MW
    J Cyst Fibros; 2015 Nov; 14(6):777-83. PubMed ID: 25921451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dornase alfa for cystic fibrosis.
    Jones AP; Wallis C
    Cochrane Database Syst Rev; 2010 Mar; (3):CD001127. PubMed ID: 20238314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung transplantation for non-cystic fibrosis bronchiectasis.
    Rademacher J; Ringshausen FC; Suhling H; Fuge J; Marsch G; Warnecke G; Haverich A; Welte T; Gottlieb J
    Respir Med; 2016 Jun; 115():60-5. PubMed ID: 27215505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of dornase alfa inhalation for cystic fibrosis.
    Dentice R; Elkins M
    Cochrane Database Syst Rev; 2011 May; (5):CD007923. PubMed ID: 21563162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa].
    Derelle J; Bertolo-Houriez E; Marchal F; Weber M; Virion JM; Vidailhet M
    Arch Pediatr; 1998 Apr; 5(4):371-7. PubMed ID: 9759155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.